Related Experiment Video
Updated: May 12, 2025

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
Published on: July 5, 2024
The Particle Size of Wheat Bran Dietary Fiber Influences Its Improvement Effects on Constipation
Luyao Li1,2, Linlin Hu1,2, Rui Chen1,2
1Key Laboratory of Geriatric Nutrition and Health, Beijing Technology and Business University (BTBU), Ministry of Education, Beijing 100048, China.
Abstract:
Wheat bran dietary fiber (WBDF) is a potential functional additive to enrich products used for relieving constipation. The purpose of this study was to understand the effects of different particle size ranges (mean sizes of 84.14, 61.74, 37.39, and 22.33 μm) of WBDF on constipation. With the decrease in particle size, its morphology exhibited an increase in fiber fragmentation, larger pore sizes, and the formation of structural faults. The oil-holding capacity (OHC) and swelling capacity (SC) of WBDF were found to change with particle size, with the highest OHC observed at 37.39 μm and the greatest SC at 84.14 μm. Animal experiments demonstrated that the WBDF of smaller particle sizes significantly alleviated loperamide-induced constipation with an increased intestinal propulsion rate, decreased first melanin excretion time, and reduced gastric residual rate. Meanwhile, WBDF samples markedly increased serum MTL and serum AChE levels. Notably, compared with the constipation model (CMNC) group, the small intestinal propulsion rate in the MPS40 group increased by 41.21%, and the gastric residue rate significantly decreased by 19.69%. The improvement in constipation symptoms was most pronounced. Additionally, the abundance of Lactobacillus in the MPS40 group increased by 52.52%, while the relative abundance of Prevotella decreased by 83.55%, and the diversity of the gut microbiota was altered. These findings provide valuable insights into the potential commercial applications of WBDF in fiber-enriched functional foods to support intestinal health.
More Related Videos
03:50Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
07:15An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Irritable Bowel Syndrome III: Medical and Nursing Management
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Digestive Functions of the Large Intestine
As the chyme moves to the colon, it triggers two characteristic sluggish contractions - haustral churning and mass peristalsis. Haustral churning involves the rhythmic contraction and relaxation...